Please select the option that best describes you:

Aside from radiation, what is your approach to patients with EGFR-mutated or ALK-translocated metastatic NSCLC who have systemic disease control but fail in the CNS?   

Do you increase the dosage of the TKI or switch to a different generation TKI? How does your answer differ for EGFR vs. ALK, and for discrete brain metastases vs. leptomeningeal disease? 


Answer from: Medical Oncologist at Academic Institution
Comments
Radiation Oncologist at Yale School of Medicine
For patients with ALK-translocated NSCLC and asymp...
Medical Oncologist at Kettering Cancer Center
What systemic treatment would you offer to a patie...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more